174 related articles for article (PubMed ID: 10647500)
1. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines.
Kröning R; Lichtenstein AK; Nagami GT
Cancer Chemother Pharmacol; 2000; 45(1):43-9. PubMed ID: 10647500
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.
Kröning R; Katz D; Lichtenstein AK; Nagami GT
Br J Cancer; 1999 Jan; 79(2):293-9. PubMed ID: 9888471
[TBL] [Abstract][Full Text] [Related]
3. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
Montine TJ; Borch RF
Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
5. cis-diamminedichloroplatinum(II) nephrotoxicity: tubular function after rescue with sodium diethyldithiocarbamate in rats.
Elliott WC; Newcom SR; Houghton DC; Baines-Hunter J; Bennett WM
Cancer Res; 1983 Aug; 43(8):3759-62. PubMed ID: 6305493
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
7. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene.
Hosoyamada M; Obinata M; Suzuki M; Endou H
Arch Toxicol; 1996; 70(5):284-92. PubMed ID: 8852699
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
Marverti G; Andrews PA
Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice.
van Angelen AA; Glaudemans B; van der Kemp AW; Hoenderop JG; Bindels RJ
Nephrol Dial Transplant; 2013 Apr; 28(4):879-89. PubMed ID: 23136218
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
13. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin.
Zheng H; Fink D; Howell SB
Clin Cancer Res; 1997 Jul; 3(7):1157-65. PubMed ID: 9815795
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of segment-specific toxicity of platinum-based agents and cadmium using S1, S2, and S3 cells derived from mouse kidney proximal tubules.
Fujishiro H; Taguchi H; Hamao S; Sumi D; Himeno S
Toxicol In Vitro; 2021 Sep; 75():105179. PubMed ID: 33905841
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
17. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.
Dickey DT; Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Sep; 314(3):1052-8. PubMed ID: 15951398
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl- L-cysteine-cDDP by TEA and PAH in the renal proximal tubule.
Kolb RJ; Ghazi AM; Barfuss DW
Cancer Chemother Pharmacol; 2003 Feb; 51(2):132-8. PubMed ID: 12647014
[TBL] [Abstract][Full Text] [Related]
19. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Feb; 312(2):424-31. PubMed ID: 15496615
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
